ReNeuron Group plc Notification of Interim Results (9315H)

TIDMRENE

RNS Number : 9315H

ReNeuron Group plc

20 November 2018

 
 AIM: RENE     20 November 2018 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Notification of Interim Results

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2018 on Friday 14 December 2018.

A meeting for analysts will be held at 9.30am on the morning of 14 December 2018 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 9.30am on the day of the results:

http://webcasting.buchanan.uk.com/broadcast/5bf3e08d1a82c37e3088a28b

A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.

ENDS

Enquiries:

 
                                               [phone] 
 ReNeuron                                       8400 
 Olav Hellebø, Chief Executive Officer 
 Michael Hunt, Chief Financial Officer 
 
                                                 [phone] 
   Buchanan                                                 5000 
 Mark Court, Sophie Wills, Tilly Abraham 
 
 Stifel Nicolaus Europe Limited 
  Jonathan Senior, Stewart Wallace, Ben        [phone] 
  Maddison (NOMAD and Joint Broker)             7600 
 
 N+1 Singer Advisory LLP                         [phone] 
  Mark Taylor (Joint Broker)                     3000 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NORBMBTTMBATBFP

(END) Dow Jones Newswires

November 20, 2018 09:00 ET (14:00 GMT)